Cargando…
Leishmania tarentolae as an Antigen Delivery Platform: Dendritic Cell Maturation after Infection with a Clone Engineered to Express the SARS-CoV-2 Spike Protein
Background: Protozoa of the genus Leishmania are characterized by their capacity to target macrophages and Dendritic Cells (DCs). These microorganisms could thus be exploited for the delivery of antigens to immune cells. Leishmania tarentolae is regarded as a non-pathogenic species; it was previousl...
Autores principales: | Varotto-Boccazzi, Ilaria, Garziano, Micaela, Cattaneo, Giulia Maria, Bisaglia, Beatrice, Gabrieli, Paolo, Biasin, Mara, Manenti, Alessandro, Rubolini, Diego, Clerici, Mario, Montomoli, Emanuele, Zuccotti, Gian Vincenzo, Trabattoni, Daria, Epis, Sara, Bandi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144667/ https://www.ncbi.nlm.nih.gov/pubmed/35632559 http://dx.doi.org/10.3390/vaccines10050803 |
Ejemplares similares
-
Epidemic Preparedness—Leishmania tarentolae as an Easy-to-Handle Tool to Produce Antigens for Viral Diagnosis: Application to COVID-19
por: Varotto-Boccazzi, Ilaria, et al.
Publicado: (2021) -
Rectal Administration of Leishmania Cells Elicits a Specific, Th1-Associated IgG2a Response in Mice: New Perspectives for Mucosal Vaccination against Leishmaniasis, after the Repurposing of a Study on an Anti-Viral Vaccine Candidate
por: Varotto-Boccazzi, Ilaria, et al.
Publicado: (2023) -
Leishmania tarentolae: a vaccine platform to target dendritic cells and a surrogate pathogen for next generation vaccine research in leishmaniases and viral infections
por: Bandi, Claudio, et al.
Publicado: (2023) -
Leishmania tarentolae: A new frontier in the epidemiology and control of the leishmaniases
por: Mendoza‐Roldan, Jairo Alfonso, et al.
Publicado: (2022) -
Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19
por: Epis, Sara, et al.
Publicado: (2022)